MYCN and neuroblastoma: The growth effects observed following I-BET726 treatment were consistent with a loss of N-Myc activity, as targeted inhibition of MYCN expression was shown to trigger growth inhibition, differentiation, and apoptosis in neuroblastoma cell lines [35,36].